Dual Antiplatelet Therapy with 3 rd Generation P2Y 12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose-Response.
Fernando ScudieroMario E CanonicoGiuseppe D SannaFilippo DossiAngelo SilverioGennaro GalassoGiovanni EspositoItalo PortoFernando ScudieroPublished in: Cardiovascular drugs and therapy (2022)
inhibitor LD, and it is a strong predictor of HTPR in STEMI patients treated by dual antiplatelet therapy with ticagrelor or prasugrel.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- coronary artery disease
- body mass index
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- atrial fibrillation
- peritoneal dialysis
- physical activity
- prognostic factors
- weight gain
- patient reported